Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics.

about

SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.Attainment of multifactorial treatment targets among the elderly in a lipid clinic Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic.

P2860

Q35669829-8D010660-74B9-44D1-BE36-CBEFC9A8E3B6 Q35697336-80EDF458-6A52-49E9-9655-F8243EC645F4 Q50684887-AE4EE2EA-19F6-451E-B224-C3FBB3B5B54F

P2860

Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics.

Item

http://www.wikidata.org/entity/Q38173637

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics.

@en

type

Item

label

Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics.

@en

prefLabel

Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics.

@en

P1476

Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics.

@en

P2093

Vasilios G Athyros

http://www.w3.org/2001/XMLSchema#string

P2860

Many roads to maturity: microRNA biogenesis pathways and their regulation

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/- mice--brief report.

Inducible ApoE gene repair in hypomorphic ApoE mice deficient in the low-density lipoprotein receptor promotes atheroma stabilization with a human-like lipoprotein profile.

AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Sub

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.

P304

72-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCARDIO.2013.209

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dimitri P Mikhailidis

P577

2013-12-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24366071

http://www.w3.org/2001/XMLSchema#string

P921

dyslipidemias

Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics.

about

P2860

P2860

Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921